Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2021 | Measuring the improvement of multiple sclerosis patients over time

Maria Pia Sormani • 6 Apr 2021
AAN 2021
Multiple Sclerosis and Related Disorders

Maria Pia Sormani, PhD, University of Genoa, Genoa, Italy, explains a project that aims to measure the improvement of multiple sclerosis patients over time. An estimator based on incidence and duration of improvement was established. This measurement can be used to analyze the effects of drugs with new mechanisms of action and give more precise information on the maintenance of improvement by patients. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.

Disclosures

Dr Maria Pia Sormani received consulting fees from Biogen, Novartis, Roche, Merck, Sanofi, Celgene, Geneuro, Immunic & Medday.

More from Maria Pia Sormani

COVID-19 vaccination in patients with MS
7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani • 13 Oct 2021
Propensity score matching to reduce confounding effects in observational studies
4:14
Propensity score matching to reduce confounding effects in observational studies
Maria Pia Sormani • 13 Oct 2021
Challenges with COVID-19 & MS registries
3:04
Challenges with COVID-19 & MS registries
Maria Pia Sormani • 13 Oct 2021
DMTs and risk for severe COVID-19 in multiple sclerosis patients
2:51
DMTs and risk for severe COVID-19 in multiple sclerosis patients
Maria Pia Sormani • 6 Apr 2021

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals